Extract: It is generally accepted that women with breast cancer (BC) have an increased risk of venous thromboembolism (VTE) compared with women of matching age, but no cancer. Metastatic disease, chemotherapy and tamoxifen treatment are all risk factors for increased VTE risk. Particularly, a 6% annual VTE incidence while undergoing chemotherapy, and up to one month after, has been recently reported in a cohort study, showing that VTE risk was markedly higher in the 3 months after initiation of tamoxifen, but not aromatase inhibitors ..
Breast cancer patients are at increased risk of VTE, particularly in the peri-diagnosis period. Howe...
Tamoxifen is an effective endocrine treatment for early breast cancer (EBC) but increases the risk o...
Abstract Background Breast cancer patients are at an increased risk of venous thromboembolism (VTE)....
Extract: It is generally accepted that women with breast cancer (BC) have an increased risk of venou...
Patients with breast cancer are at increased risk of venous thromboembolism (VTE), particularly in t...
Breast cancer patients are at increased risk of VTE, particularly in the peri-diagnosis period. Howe...
Breast cancer patients are at increased risk of VTE, particularly in the peri-diagnosis period. Howe...
Albeit it does not have the highest venous thromboembolism (VTE) incidence compared to other neoplas...
18Background - Tamoxifen, a selective estrogen-receptor modulator, increases venous thromboembolic e...
Background: Estimates of the risk ratio of tamoxifen-associated venous thromboembolism(VTE) in breas...
Venous thromboembolism (VTE) is a major common complication in cancer patients. Risk-adapted thrombo...
Abstract BACKGROUND: Tamoxifen, a selective estrogen-receptor modulator, increases venous thromboemb...
International audienceVenous thromboembolism (VTE) is a major common complication in cancer patients...
Background—Tamoxifen, a selective estrogen-receptor modulator, increases venous thromboembolic event...
International audienceThere is a strong association between cancer and venous thromboembolism (VTE)....
Breast cancer patients are at increased risk of VTE, particularly in the peri-diagnosis period. Howe...
Tamoxifen is an effective endocrine treatment for early breast cancer (EBC) but increases the risk o...
Abstract Background Breast cancer patients are at an increased risk of venous thromboembolism (VTE)....
Extract: It is generally accepted that women with breast cancer (BC) have an increased risk of venou...
Patients with breast cancer are at increased risk of venous thromboembolism (VTE), particularly in t...
Breast cancer patients are at increased risk of VTE, particularly in the peri-diagnosis period. Howe...
Breast cancer patients are at increased risk of VTE, particularly in the peri-diagnosis period. Howe...
Albeit it does not have the highest venous thromboembolism (VTE) incidence compared to other neoplas...
18Background - Tamoxifen, a selective estrogen-receptor modulator, increases venous thromboembolic e...
Background: Estimates of the risk ratio of tamoxifen-associated venous thromboembolism(VTE) in breas...
Venous thromboembolism (VTE) is a major common complication in cancer patients. Risk-adapted thrombo...
Abstract BACKGROUND: Tamoxifen, a selective estrogen-receptor modulator, increases venous thromboemb...
International audienceVenous thromboembolism (VTE) is a major common complication in cancer patients...
Background—Tamoxifen, a selective estrogen-receptor modulator, increases venous thromboembolic event...
International audienceThere is a strong association between cancer and venous thromboembolism (VTE)....
Breast cancer patients are at increased risk of VTE, particularly in the peri-diagnosis period. Howe...
Tamoxifen is an effective endocrine treatment for early breast cancer (EBC) but increases the risk o...
Abstract Background Breast cancer patients are at an increased risk of venous thromboembolism (VTE)....